Characterization of monoamine oxidases in mesenchymal stem cells: Role in hydrogen peroxide generation and serotonin-dependent apoptosis

Stem Cells and Development

Volumn 19, Issue 10, 2010, Pages 1571-1578

  Trouche, Elodie ^a   Mias, Celine ^a   Seguelas, Marie Helene ^a   Ordener, Catherine ^a   Cussac, Daniel ^a   Parini, Angelo ^a,b  

^a CHU RANGUEIL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; HYDROGEN PEROXIDE; IMIPRAMINE; PARGYLINE; PHENETHYLAMINE; PROTEIN BCL 2; SEROTONIN; SEROTONIN TRANSPORTER; TYRAMINE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; ENZYME ASSAY; MESENCHYMAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELLS, CULTURED; CYTOCHROMES C; HYDROGEN PEROXIDE; IMIPRAMINE; ISOENZYMES; MESENCHYMAL STEM CELLS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; OXIDANTS; PARGYLINE; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, INBRED LEW; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYMPATHOMIMETICS; TYRAMINE;

EID: 77957560303     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2009.0353     Document Type: Article

References (53)

1. Beyer Nardi N and L da Silva Meirelles. (2006). Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol 174:249-282.
2. Jiang Y, BN Jahagirdar, RL Reinhardt, RE Schwartz, CD Keene, XR Ortiz-Gonzalez, M Reyes, T Lenvik, T Lund, M Blackstad, J Du, S Aldrich, A Lisberg, WC Low, DA Largaespada and CM Verfaillie. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41-49.
3. Kassem M, M Kristiansen and BM Abdallah. (2004). Mesenchymal stem cells: cell biology and potential use in therapy. Basic Clin Pharmacol Toxicol 95:209-214.
4. Kudryavtsev YV, VI Kirpatovskii, EY Plotnikov, AV Kazachenko, MV Marei, TG Khryapenkova, DB Zorov and GT Sukhikh. (2009). Morphological changes in the kidneys of rats with postishemic acute renal failure after intrarenal administration of fetal mesenchymal stem cells from human bone marrow. Bull Exp Biol Med 147:113-119.
5. Mias C, O Lairez, E Trouche, J Roncalli, D Calise, MH Seguelas, C Ordener, MD Piercecchi-Marti, N Auge, AN Salvayre, P Bourin, A Parini and D Cussac. (2009). Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells 27:2734-2743.
6. Hopkins C, J Li., F Rae and MH Little. (2009). Stem cell options for kidney disease. J Pathol 217:265-281.
7. Mias C, E Trouche, MH Seguelas, F Calcagno, F Dignat-George, F Sabatier, MD Piercecchi-Marti, L Daniel, P Bianchi, D Calise, P Bourin, A Parini and D Cussac. (2008). Ex vivo pretreatment with melatonin improves survival, proangiogenic/mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney. Stem Cells 26:1749-1757
8. Müller-Ehmsen J., P Whittaker, RA Kloner, JS Dow, T Sakoda, TI Long, PW Laird and L Kedes. (2002). Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol 34:107-116.
9. Reinecke H, M Zhang, T Bartosek and CE Murry. (1999). Survival, integration, and differentiation of cardiomyocyte grafts: a study in normal and injured rat hearts. Circulation 100:193-202.
10. Toma C, MF Pittenger, KS Cahill, BJ Byrne and PD Kessler. (2002). Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105:93-98.
11. Niagara MI, HKh Haider, S Jiang and M Ashraf. (2007). Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res 100:545-555.
12. Suzuki K, B Murtuza, JR Beauchamp, RT Smolenski, A Varela-Carver, S Fukushima, SR Coppen, TA Partridge and MH Yacoub. (2004). Dynamics and mediators of acute graft attrition after myoblast transplantation to the heart. FASEB J 18:1153-1155. (Pubitemid 39561554)
13. Suzuki K, RT Smolenski, J Jayakumar, B Murtuza, NJ Brand and MH Yacoub. (2000). Heat shock treatment enhances graft cell survival in skeletal myoblast transplantation to the heart. Circulation 102:111216-221.
14. Tang YL, Y Tang, YC Zhang, K Qian, L Shen and MI Phillips. (2005). Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol 46:1339-1350.
15. Bianchi P, O Kunduzova, E Masini, C Cambon, D Bani, L Raimondi, MH Seguelas, S Nistri, W Colucci, N Leducq and A Parini. (2005). Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation 112:3297-3305.
16. Coatrieux C, M Sanson, A Negre-Salvayre, A Parini, Y Hannun, S Itohara, R Salvayre and N Auge. (2007). MAO-A-induced mitogenic signaling is mediated by reactive oxygen species, MMP-2, and the sphingolipid pathway. Free Radie Biol Med 43:80-89.
17. Pchejetski D, O Kunduzova, A Dayon, D Calise, MH Seguelas, N Leducq, I Seif, A Parini and O Cuvillier. (2007). Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res 100:41-49.
18. Abell CW and SW Kwan. (2001). Molecular characterization of monoamine oxidases A and B. Prog Nucleic Acid Res Mol Biol 65:129-156.
19. Upadhyay, AK and DE Edmondson. (2009). Development of spin-labeled pargyline analogues as specific inhibitors of human monoamine oxidases A and B. Biochemistry 48:3928-3935.
20. Billett EE. (2004). Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicology 25:139-148.
21. Agostinelli E, G Arancia, LD Vedova, F Belli, M Marra, M Salvi and A Toninello. (2004). The biological functions of polyamine oxidation products by amine oxidases: perspectives of clinical applications. Amino Acids 27:347-358.
22. Kopin IJ. (1994). Monoamine oxidase and catecholamine metabolism. J Neural Transm Suppl 41:57-67
23. Bianchi P, DR Pimentel, MP Murphy, WS Colucci and A Parini. (2005). A new hypertrophic mechanism of serotonin in cardiac myocytes: receptor-independent ROS generation. FASEB J 19:641-643.
24. Jin HK, JS Bae, S Furuya and JE Carter. (2009). Amyloid beta-derived neuroplasticity in bone marrow-derived mesenchymal stem cells is mediated by NPY and 5-HT2B receptors via ERK1/2 signalling pathways. Cell Prolif 42:571-586.
25. Gustafsson BI, L Thommesen, AK Stunes, K Tommeras, I Westbroek, HL Waldum, K Slordahl, MV Tamburstuen, JE Reseland and U Syversen. (2006). Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem 98:139-151.
26. Stuck BJ, M Lenski, M Böhm and U Laufs. (2008). Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J Biol Chem 283:32562-32569.
27. Pizzinat N, N Copin, C Vindis, A Parini and C Cambon. (1999). Reactive oxygen species production by monoamine oxidases in intact cells. Naunyn Schmiedebergs Arch Pharmacol 359:428-431.
28. Maurel A, C Hernandez, O Kunduzova, G Bompart, C Cambon, A Parini and B Francés. (2003). Age-dependent increase in hydrogen peroxide production by cardiac monoamine oxidase A in rats. Am J Physiol Heart Circ Physiol 284:H1460-H1467
29. Marcocci L, U De Marchi, M Salvi, ZG Milella, S Nocera, E Agostinelli, B Mondovi and A Toninello. (2002). Tyramine and monoamine oxidase inhibitors as modulators of the mitochondrial membrane permeability transition. J Membr Biol 188:23-31.
30. Lemasters JJ, TP Theruvath, Z Zhong and AL Nieminen. (2009). Mitochondrial calcium and the permeability transition in cell death. Biochim Biophys Acta 1787:1395-1401.
31. Nandigama RK, JR Miller and DE Edmondson. (2001). Loss of serotonin oxidation as a component of the altered substrate specificity in the Y444F mutant of recombinant human liver MAO A. Biochemistry 40:14839-14846.
32. Wells SM, MC Buford, VM Porter, HL Brunell, M Bunderson-Schelvan, AB Nevin, F Cardozo-Pelaez and A Holian. (2009). Role of the Serotonergic System in Reduced Pulmonary Function Following Exposure to Methamphetamine. Am J Respir Cell Mol Biol. Jun 18 [Epub ahead of print]; DOI: 10.1165/rcmb.2009-0121OC.
33. Launay JM, B Schneider, S Loric, M Da Prada and O Kellermann. (2006). Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells. FASEB J 20:1843-1854.
34. Millan MJ. (2006). Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 110:135-370.
35. Millan MJ, P Marin, J Bockaert and CM la Cour. (2008). Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci 29:454-464.
36. Walther DJ, JU Peter, S Winter, M Höltje, N Paulmann, M Grohmann, J Vowinckel, V Alamo-Bethencourt, CS Wilhelm, G Ahnert-Hilger and M Bader. (2003). Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 115:851-862.
37. Fu LW and JC Longhurst. (2002). Activated platelets contribute to stimulation of cardiac afferents during ischaemia in cats: role of 5-HT(3) receptors. J Physiol (Lond) 544(PART 3):897-912.
38. Longhurst JC, SC Tjen-A-Looi and LW Fu. (2001). Cardiac sympathetic afferent activation provoked by myocardial ischemia and reperfusion.Mechanisms and reflexes Ann N Y Acad Sci 940:74-95.
39. Shimizu Y, S Minatoguchi, K Hashimoto, Y Uno, M Arai, N Wang, X Chen, C Lu, G Takemura, M Shimomura, T Fujiwara and H Fujiwara. (2002). The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts. J Am Coll Cardiol 40:1347-1355.
40. Barradas MA, DS Gill, VA Fonseca, DP Mikhailidis and P Dandona. (1988). Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 18:399-404.
41. Malyszko J, T Urano, R Knofler, A Taminato, T Yoshimi, Y Takada and A Takada. (1994). Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res 75:569-576.
42. Hara K, Y Hirowatari, M Yoshika, Y Komiyama, Y Tsuka and H Takahashi. (2004). The ratio of plasma to whole-blood serotonin may be a novel marker of atherosclerotic cardiovascular disease. J Lab Clin Med 144:31-37
43. Hilton BP and JN Cumings. (1971). An assessment of platelet aggregation induced by 5-hydroxytryptamine. J Clin Pathol 24:250-258.
44. Kasperska-Zajac A., Z Brzoza and B Rogala. (2008). Platelet function in cutaneous diseases. Platelets 19:317-321.
45. Rex S, LM Beaulieu, DH Perlman, O Vitseva, PS Blair, ME McComb, CE Costello and JE Freedman. (2009). Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein-protein interactions, and alpha-granule release. Thromb Haemost 102:97-110.
46. Sowa JM, SA Crist, TL Ratliff and BD Elzey. (2009). Platelet influence on T-and B-cell responses. Arch Immunol Ther Exp (Warsz) 57:235-241.
47. Collet C, C Schiltz, V Geoffroy, L Maroteaux, JM Launay and MC de Vernejoul. (2008). The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J 22:418-427
48. Yabanoglu S, M Akkiki, MH Seguelas, J Mialet-Perez, A Parini and N Pizzinat. (2009). Platelet derived serotonin drives the activation of rat cardiac fibroblasts by 5-HT2A receptors. J Mol Cell Cardiol 46:518-525.
49. Yang M, K L.i., PC Ng, CK Chuen, TK Lau, YS Cheng, YS Liu, CK Li, PM Yuen, AE James, SM Lee and TF Fok. (2007). Promoting effects of serotonin on hematopoiesis: ex vivo expansion of cord blood CD34+ stem/progenitor cells, proliferation of bone marrow stromal cells, and antiapoptosis. Stem Cells 25:1800-1806.
50. Stolzing A, E Jones, D McGonagle and A Scutt. (2008). Agerelated changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 129:163-173.
51. Stolzing A and A Scutt. (2006). Effect of reduced culture temperature on antioxidant defences of mesenchymal stem cells. Free Radic Biol Med 41:326-338.
52. Kornhuber J, C Konradi, F Mack-Burkhardt, P Riederer, H Heinsen and H Beckmann. (1989). Ontogenesis of monoamine oxidase-A and -B in the human brain frontal cortex. Brain Res 499:81-86.
53. Savitha S, B Naveen and C Panneerselvam. (2007). Carnitine and lipoate ameliorates lipofuscin accumulation and monoamine oxidase activity in aged rat heart. Eur J Pharmacol 574:61-65.